A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Helicobacter pylori infection is associated with several gastric diseases, including
gastritis, peptic and duodenal ulcers, gastric carcinoma and MALToma. In 1994, the WHO
classified the organism as a type 1 carcinogen. In order to eradicate H. pylori, at least two
antibiotics and a proton pump inhibitor are used as a standard therapy regimen. Emerging
antibiotic resistance to metronidazole or clarithromycin, however, has made successful
treatment of infection progressively more difficult, with the success rate of standard triple
therapy now at 70%, well below the 80% required for treatment of infectious diseases.
Therefore, new treatment regimen is required for successful H. pylori eradication.
On the other hands, many in vitro studies revealed that bacterial carbonic anhydrase in H.
pylori has an important role for surviving of H. pylori in the stomach. It was demonstrated
that mutation of carbonic anhydrase affected survival of H. pylori. The investigators
therefore expected that administration of carbonic anhydrase inhibitor (acetazolamide) with
standard H. pylori eradication regimen would increase the eradication rate. Here, the
investigators aim to evaluate the efficacy of standard triple regimen plus acetazolamide for
H. pylori eradication.